Chemical structure of IM156

oral protein-complex 1 (OXPHOS) inhibitor

200-800 mg QD, phase I, cancer/IPF

from metformin

J. Pharmacol. Exp. Ther.

ImmunoMet Therapeutics

The ImmunoMet OXPHOS modulator (PC1 inhibitor), IM156, is a derivative of the long-used biguanide diabetes drug, metformin, that appears to have activity in lung fibrosis models. The therapeutic hypothesis for…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.